PTGS2 and glaucoma: Since AEA and 2-AG can be converted in reactions catalyzed by COX-2 to prostaglandins and chemically related prostamides, whose analog, e.g., bimatoprost, plays a crucial role in glaucoma treatment, it is believed that endocannabinoids can modulate the uveoscleral outflow, resulting in IOP reduction (35, 36).